This approval enables the company to begin marketing aegis products for sale in the EU. Peripatch aegis is a buttressing material designed to reinforce the staple line and prevent bleeding and leaks during bariatric and thoracic endoscopic surgical procedures. Peripatch aegis products will be marketed in Europe through Neovasc’s network of independent distributors.
Separately, Neovasc also announced changes to its senior management team. The company has appointed Cynthia Roney to the expanded role of vice president, sales and marketing, adding the responsibilities of the former position of vice president, sales to her portfolio. In addition, Neovasc named Fabio Pasquale as director of regulatory affairs.
Alexei Marko, CEO of Neovasc, said: “Leakage in endoscopic procedures can result in serious complications for patients, so we specifically designed Peripatch aegis to enable endoscopic surgeons to reinforce surgical staple lines efficiently and effectively. We are pleased to have received regulatory clearance to now make this superior product available to surgeons in Europe.”